# Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Source: https://onco.cc/trials/nct04494503/  
OnCo record `nct04494503` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rituximab and Ibrutinib in chronic lymphocytic leukaemia, run by Ascentage Pharma Group Inc., now recruiting.

## Summary

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL is a phase 1/2 interventional study registered as NCT04494503 by Ascentage Pharma Group Inc., with 123 participants planned, started 2020-08-31 and due to reach its primary completion in 2024-10-20. Interventions recorded: APG-2575, Rituximab and Ibrutinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04494503
- Phase: 1/2
- Setting: A Phase Ib/II Study of the Safety, Pharmacokinetic, Pharmacodynamic and Efficacy of APG-2575 Single Agent and in Combination With Other Therapeutic Agents in Patients With Relapsed/Refractory CLL/SLL
- Sponsor: Ascentage Pharma Group Inc.
- Enrolled: 123

## Sources

- ClinicalTrials.gov NCT04494503: https://clinicaltrials.gov/study/NCT04494503

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04494503.json